focus -WSS

focus

author：fashion 2025-08-23 05:01:15 - browse：9392

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Maker of FluMist seeks to allow at

focus

WSS

Weight bias in eating disorder treatment complicated by new weight loss drugs

CDC recommends rationing of RSV shot due to shortages

WATCH: Why do fingernails fall off when they're damaged?

Paxlovid study fails to answer questions over benefit for broader groups

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

The FDA weighs the risks of candy

explore

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

Wildfire smoke exposes gaps in outdoor worker protections

In areas with more Black doctors, Black people live longer

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

With FDA staff opposed to Sarepta therapy, top official intervened

Guidelines to prevent youth baseball injuries need more muscle

Why drug prescriptions should include diagnoses

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Chimpanzees, like humans and whales, get menopause: Study

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Why we need to separate burnout from moral injury in health care

leisure time

Readout Newsletter: What happened with Sarepta's Duchenne data

Disclosing genetic information: not as worrisome as once feared

Hospitals warn Medicare's drug payment fix is ‘unlawful’

Cloning humans is technically possible. It's curious no one has tried

Emergency medicine has repudiated 'excited delirium.' Now what?

First Opinion Podcast: How to protect health care in times of war

focus

leisure time

hotspot

explore